139 related articles for article (PubMed ID: 2718605)
21. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
22. Liposomes as vehicles for vaccines.
Alving CR; Banerji B; Shiba T; Kotani S; Clements JD; Richards RL
Prog Clin Biol Res; 1980; 47():339-55. PubMed ID: 7208512
[TBL] [Abstract][Full Text] [Related]
23. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives.
Jain V; Vyas SP; Kohli DV
Nanomedicine; 2009 Sep; 5(3):334-44. PubMed ID: 19523433
[TBL] [Abstract][Full Text] [Related]
24. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
25. Biological studies of lipophilic MDP-derivatives incorporated in liposomes.
Jolivet M; Sache E; Audibert F
Immunol Commun; 1981; 10(6):511-22. PubMed ID: 7319546
[TBL] [Abstract][Full Text] [Related]
26. Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses.
Nerome K; Yoshioka Y; Ishida M; Okuma K; Oka T; Kataoka T; Inoue A; Oya A
Vaccine; 1990 Oct; 8(5):503-9. PubMed ID: 2251876
[TBL] [Abstract][Full Text] [Related]
27. Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
Effenberg R; Turánek Knötigová P; Zyka D; Čelechovská H; Mašek J; Bartheldyová E; Hubatka F; Koudelka Š; Lukáč R; Kovalová A; Šaman D; Křupka M; Barkocziova L; Kosztyu P; Šebela M; Drož L; Hučko M; Kanásová M; Miller AD; Raška M; Ledvina M; Turánek J
J Med Chem; 2017 Sep; 60(18):7745-7763. PubMed ID: 28829599
[TBL] [Abstract][Full Text] [Related]
28. Effect of a synthetic adjuvant for inducing anti-tumour immunity.
Kataoka T; Kinomoto M; Takegawa M; Tokunaga T
Vaccine; 1991 May; 9(5):300-2. PubMed ID: 1872013
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant formulations and their mode of action.
Allison AC; Byars NE
Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859
[TBL] [Abstract][Full Text] [Related]
30. In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde.
Parant M; Damais C; Audibert F; Parant F; Chedid L; Sache E; Lefrancier P; Choay J; Lederer E
J Infect Dis; 1978 Sep; 138(3):378-86. PubMed ID: 100563
[TBL] [Abstract][Full Text] [Related]
31. Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine).
Mozes E; Sela M; Chedid L
Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4933-7. PubMed ID: 6776530
[TBL] [Abstract][Full Text] [Related]
32. Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP.
Ando S; Tsuge H; Mayumi T
J Microencapsul; 1997; 14(1):79-90. PubMed ID: 8994077
[TBL] [Abstract][Full Text] [Related]
33. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
Ishida H; Saiki I; Saito S; Hasegawa A; Kiso M; Azuma I
Vaccine; 1988 Oct; 6(5):440-4. PubMed ID: 3195200
[TBL] [Abstract][Full Text] [Related]
34. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease.
Ishihara C; Miyazawa M; Nishio J; Azuma I; Chesebro B
Vaccine; 1992; 10(5):353-6. PubMed ID: 1574922
[TBL] [Abstract][Full Text] [Related]
35. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
36. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382).
Kaji M; Kaji Y; Kaji M; Ohkuma K; Honda T; Oka T; Sakoh M; Nakamura S; Kurachi K; Sentoku M
Vaccine; 1992; 10(10):663-7. PubMed ID: 1523876
[TBL] [Abstract][Full Text] [Related]
38. Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide, re-glycolipid, lipid A, and muramyl dipeptide.
Kotani S; Takada H; Tsujimoto M; Ogawa T; Mori Y; Sakuta M; Kawasaki A; Inage M; Kusumoto S; Shiba T; Kasai N
Infect Immun; 1983 Aug; 41(2):758-73. PubMed ID: 6409812
[TBL] [Abstract][Full Text] [Related]
39. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant activities of quinonyl-N-acetyl muramyl dipeptides in mice and guinea pigs.
Saiki I; Tanio Y; Yamawaki M; Uemiya M; Kobayashi S; Fukuda T; Yukimasa H; Yamamura Y; Azuma I
Infect Immun; 1981 Jan; 31(1):114-21. PubMed ID: 6971259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
